Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 75 entries
View as:

Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00269867 Org: User:
Start: 03/31/97 End: 03/31/00 Due: 03/31/01

An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00402181 Org: User:
Start: 10/31/06 End: 07/31/09 Due: 07/31/10

An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00269841 Org: User:
Start: 05/31/96 End: 02/28/98 Due: 02/28/99

An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00267956 Org: User:
Start: 12/31/05 End: 09/30/07 Due: 09/30/08

Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis

Phase: N/A Priority: Normal
NCT ID: NCT01248793 Org: User:
Start: 10/31/10 End: 03/31/12 Due: 03/31/13

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

Phase: N/A Priority: Normal
NCT ID: NCT00046228 Org: User:
Start: 08/31/02 End: 01/31/08 Due: 01/31/09

A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00265135 Org: User:
Start: 08/31/03 End: 02/28/06 Due: 02/28/07

A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00051623 Org: User:
Start: 05/31/03 End: 06/30/04 Due: 06/30/05

A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01195207 Org: User:
Start: 06/30/10 End: 01/31/12 Due: 01/31/13

A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT00844909 Org: User:
Start: 01/31/09 End: 08/31/09 Due: 08/31/10

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01266811 Org: User:
Start: 07/31/11 End: 12/31/14 Due: 12/31/15

A Long-term Safety Study of Infliximab (Remicade)

Phase: N/A Priority: Normal
NCT ID: NCT00261976 Org: User:
Start: 02/28/02 End: 03/31/12 Due: 03/31/13

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

Phase: N/A Priority: Normal
NCT ID: NCT00269906 Org: User:
Start: 05/31/93 End: 12/31/95 Due: 12/31/96

A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00320216 Org: User:
Start: 11/30/03 End: 03/31/05 Due: 03/31/06

A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00718718 Org: User:
Start: 08/11/08 End: 03/03/11 Due: 03/03/12

A Study of Infliximab in Patients With Sarcoidosis

Phase: N/A Priority: Normal
NCT ID: NCT00073437 Org: User:
Start: 10/31/03 End: 02/28/05 Due: 02/28/06

Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01248780 Org: User:
Start: 09/30/10 End: 07/31/12 Due: 07/31/13

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02074800 Org: User:
Start: 06/30/08 End: 06/30/09 Due: 06/30/10

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase: N/A Priority: Normal
NCT ID: NCT00385827 Org: User:
Start: 11/30/06 End: 11/30/08 Due: 11/30/09

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA)

Phase: N/A Priority: Normal
NCT ID: NCT01362153 Org: User:
Start: 12/26/07 End: 02/27/09 Due: 02/27/10

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty

Phase: N/A Priority: Normal
NCT ID: NCT00269893 Org: User:
Start: 11/30/91 End: 11/30/92 Due: 11/30/93

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00246012 Org: User:
Start: 05/31/05 End: 02/28/09 Due: 02/28/10

A Study of the Safety and Efficacy of Infliximab in Patients With Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00106834 Org: User:
Start: - End: 10/31/04 Due: 10/31/05

A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT00786201 Org: User:
Start: 12/31/08 End: 01/31/12 Due: 01/31/13

A Safety and Efficacy Study for Infliximab (Remicade) With Methotrexate in Patients With Early Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00236028 Org: User:
Start: - End: 04/30/03 Due: 04/30/04